Pharmatherapeutica最新文献_第6页

Acute functional psychoses: treatment with zuclopenthixol dihydrochloride ('Clopixol') tablets. 急性功能性精神病:用盐酸夏绿戊硫醇片治疗。

Pharmatherapeutica Pub Date : 1987-01-01

S N Bhattacharyya, J Ghoshal, S K Sharma, N Halstead, B John, M A Launer, P K Mukherjee, A S Zigmond

{"title":"Acute functional psychoses: treatment with zuclopenthixol dihydrochloride ('Clopixol') tablets.","authors":"S N Bhattacharyya, J Ghoshal, S K Sharma, N Halstead, B John, M A Launer, P K Mukherjee, A S Zigmond","doi":"","DOIUrl":"","url":null,"abstract":"An assessment of the efficacy and tolerability of zuclopenthixol dihydrochloride tablets in the treatment of acute psychotic episodes was undertaken in 63 patients in an open multi-centre study. Most patients prior to entering the study had received other neuroleptic drugs, but with inadequate effect. During the 10-week study, the dosage of zuclopenthixol dihydrochloride tablets could be adjusted to obtain optimum clinical benefit. The majority of patients received 20 to 75 mg daily (range 10 to 150 mg daily) at the start of the study and later, for most of those patients successfully treated, the dosage was 20 to 55 mg daily. Assessments before and during treatment utilized the BPRS and CGI rating scales and a check-list of side-effects. A successful response to treatment was achieved in 70% of 50 patients with schizophrenia or schizophreniform psychoses and in 69% of 13 patients with mania or hypomania. Almost half (30) of the patients studied had a successful response within 4 weeks of starting treatment and some after only 1 week of treatment. All patients but 1 had either no side-effects or side-effects not overtly affecting performance.","PeriodicalId":19862,"journal":{"name":"Pharmatherapeutica","volume":"5 1","pages":"1-8"},"PeriodicalIF":0.0,"publicationDate":"1987-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14723021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The combination of verapamil and captopril in the treatment of essential hypertension. 维拉帕米联合卡托普利治疗原发性高血压的疗效观察。

Pharmatherapeutica Pub Date : 1987-01-01

A M Heagerty, J D Swales

{"title":"The combination of verapamil and captopril in the treatment of essential hypertension.","authors":"A M Heagerty, J D Swales","doi":"","DOIUrl":"","url":null,"abstract":"A single-blind trial was carried out in 18 patients with moderately severe hypertension to investigate the efficacy of the angiotensin-converting enzyme inhibitor captopril in combination with the calcium antagonist verapamil after treatment with captopril alone had failed to achieve satisfactory control. For the first 2 weeks of the study, patients received 50 mg captopril twice daily, then 50 mg captopril plus 160 mg verapamil twice daily for 4 weeks, followed by 160 mg verapamil twice daily for a further 4 weeks. The double-dummy technique was used with placebo tablets given during the first and last treatment periods. Blood pressure and heart rate measurements in the supine and standing position were made at 2-week intervals throughout the study. Analysis of the results from the 13 patients who completed the trial protocol showed that the two drugs in combination produced significant reductions (p less than 0.01) in both supine and standing blood pressures compared with captopril alone, but a significant reduction (p less than 0.02) only in diastolic blood pressure compared with verapamil alone. Heart rate was not changed significantly throughout the study. Only 1 patient was withdrawn because of side-effects, although on questioning constipation, in particular, proved to be a problem in many.","PeriodicalId":19862,"journal":{"name":"Pharmatherapeutica","volume":"5 1","pages":"21-5"},"PeriodicalIF":0.0,"publicationDate":"1987-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14427954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A 6-month, double-blind study comparing nabumetone to naproxen in the treatment of osteoarthritis. 一项为期6个月的双盲研究，比较纳布美酮和萘普生治疗骨关节炎的疗效。

Pharmatherapeutica Pub Date : 1987-01-01

E J Pisko, K Strader, D Rice, R White, L A Goodman

{"title":"A 6-month, double-blind study comparing nabumetone to naproxen in the treatment of osteoarthritis.","authors":"E J Pisko, K Strader, D Rice, R White, L A Goodman","doi":"","DOIUrl":"","url":null,"abstract":"A 6-month, double-blind, controlled, randomized, parallel study was performed to compare the efficacy and tolerance of nabumetone (1000 mg at bedtime) with naproxen (250 mg twice daily) in the treatment of osteoarthritis. Five efficacy parameters were evaluated: patient's assessment of overall osteoarthritis activity and pain, physician's assessment of overall osteoarthritis activity and pain, and physician's assessment of pain with respect to a defined activity. All 40 patients entered (20 in each group) were available for evaluation of tolerance and 36 patients for efficacy analysis (18 in each group). The efficacy results revealed significant improvement in all five parameters for each medication except measurement of pain with respect to a defined activity for naproxen (p less than 0.07). The frequency of possible or probable drug-related adverse experiences was high for both drugs. However, only 1 patient left the study because of a probable drug-related adverse experience (abdominal pain in a nabumetone patient). Six nabumetone and 4 naproxen patients dropped out of the study because of lack of efficacy. The results indicate that nabumetone and naproxen have comparable efficacy and tolerance at the dosage used, and suggest that a single night-time dosage of nabumetone may be a convenient and useful treatment for osteoarthritis.","PeriodicalId":19862,"journal":{"name":"Pharmatherapeutica","volume":"5 2","pages":"90-8"},"PeriodicalIF":0.0,"publicationDate":"1987-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14438300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A randomized study of two preparations for large bowel radiology. 两种大肠放射学制剂的随机研究。

Pharmatherapeutica Pub Date : 1987-01-01

B S Strates, L M Hofmann

引用次数: 0

Efficacy and tolerance of naproxen versus pirprofen in the treatment of patients with osteoarthritis. 萘普生与吡洛芬治疗骨关节炎的疗效和耐受性比较。

Pharmatherapeutica Pub Date : 1987-01-01

I Boussina, T L Vischer

引用次数: 0

Affective disorders in general practice. Treatment of 6000 patients with fluvoxamine. 一般实践中的情感性障碍。氟伏沙明治疗6000例患者。

Pharmatherapeutica Pub Date : 1987-01-01

A J Martin, V M Tebbs, J J Ashford

{"title":"Affective disorders in general practice. Treatment of 6000 patients with fluvoxamine.","authors":"A J Martin, V M Tebbs, J J Ashford","doi":"","DOIUrl":"","url":null,"abstract":"A total of 6258 patients seen in general practice complaining of low mood with or without associated somatic symptoms was studied. The mean patient entry score on the Montgomery-Asberg Depression Rating Scale (MADRS) was 29.69 (moderately severe depressive disorder). Three-quarters (73%) of the patients were female, average age was 46.1 years, and a reactive element was considered to be present in 43%. Patients received fluvoxamine, a novel anti-depressant, over a treatment period of 6 weeks, dosage starting at either 50 or 100 mg at night increasing after the first week, if necessary, to a maximum of 300 mg per day. Results were analyzed for 5625 patients. Efficacy of treatment was assessed using the MADRS, Psychosomatic Symptom Scale and Clinical Global Impression scales. During treatment, there was a marked improvement in mood and a parallel improvement in somatic symptoms; there was no difference in overall response between those with or without somatic symptoms. By Week 6, patients had improved by approximately 65%, with suicidal ideation being most marked at 81%. Patient compliance was good, the most commonly reported unwanted effect being nausea. In overdoses up to 2 g fluvoxamine no lasting toxic effects were observed. In an 'elderly' sub-group of 1096 patients aged 60 years and over, efficacy and the incidence of unwanted effects were similar, but the drop-out rate due to intolerance was greater than in the younger age sub-group.","PeriodicalId":19862,"journal":{"name":"Pharmatherapeutica","volume":"5 1","pages":"40-9"},"PeriodicalIF":0.0,"publicationDate":"1987-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14241211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A clinical trial of hydrocortisone/potassium hydroxyquinoline sulphate ('Quinocort') in the treatment of infected eczema and impetigo in general practice. 氢化可的松/硫酸羟基喹啉钾(“喹诺柯”)治疗感染性湿疹和脓疱疮的临床试验

Pharmatherapeutica Pub Date : 1986-01-01

G V Jaffé, J J Grimshaw

{"title":"A clinical trial of hydrocortisone/potassium hydroxyquinoline sulphate ('Quinocort') in the treatment of infected eczema and impetigo in general practice.","authors":"G V Jaffé, J J Grimshaw","doi":"","DOIUrl":"","url":null,"abstract":"A double-blind, multi-centre study was carried out in general practice in 76 patients with infected eczema and 43 with impetigo to assess the effectiveness and acceptability of treatment with 1% hydrocortisone plus 0.5% potassium hydroxyquinoline sulphate cream compared with that of 1% hydrocortisone plus 2% miconazole nitrate cream. Patients were allocated at random to receive treatment with one or other preparation, applied twice daily, over a period of 2 weeks. Assessments were made of total symptom severity scores on entry and at the end of each week, as also were bacteriological investigations. The results showed that both combinations produced marked clinical and bacteriological improvement or cure in approximately 90% of patients with infected eczema and the success rate was similar with each preparation. In the case of patients with impetigo, hydrocortisone/potassium hydroxyquinoline sulphate proved significantly more effective than the other combination, the success rates being 92% and 74%, respectively. Patient assessment of the two topical preparations in terms of greasiness, odour and staining showed that, whilst both were considered acceptable by most, there was a trend in favour of the hydrocortisone/potassium hydroxyquinoline sulphate cream. No systemic or local side-effects were reported.","PeriodicalId":19862,"journal":{"name":"Pharmatherapeutica","volume":"4 10","pages":"628-36"},"PeriodicalIF":0.0,"publicationDate":"1986-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14427952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fenoverine: a two-step, double-blind and open clinical assessments of its smooth muscle synchronizing effects. 非诺overine:对其平滑肌同步效应的两步、双盲和开放临床评估。

Pharmatherapeutica Pub Date : 1986-01-01

F Bader

{"title":"Fenoverine: a two-step, double-blind and open clinical assessments of its smooth muscle synchronizing effects.","authors":"F Bader","doi":"","DOIUrl":"","url":null,"abstract":"A clinical trial on fenoverine was performed in two parts, one double-blind and one open. In the double-blind segment, 69 patients with chronic gastro-intestinal spasmodic conditions were allocated, according to a pre-set randomization table, to receive orally 3 daily doses of fenoverine (100 mg; 35 patients), trimebutine (150 mg; 14 patients) or placebo (20 patients) during an average of 8 days. In the open assay, 60 similar patients were treated during an average of 10 days with 100 mg fenoverine, orally, 3-times daily. Clinical efficacy was evaluated on the grounds of complete or almost complete remission of all symptoms and signs associated with the spasmodic condition. In the double-blind segment, 66% of patients given fenoverine experienced remission, a significantly higher proportion than those who had placebo (40%). The results with trimebutine (71%) could not be statistically differentiated from those of either fenoverine or placebo. In the open segment, 72% of patients experienced remission with fenoverine, thus showing an overall effectiveness in 70% of the total 95 patients who had such treatment. In neither study could a significant influence of spasm localization be shown on the clinical efficacy of fenoverine. Fenoverine also exerted an unexpected, though clinically interesting, anti-emetic action: of the 14 patients reporting vomiting on entry, 12 (86%) responded positively to fenoverine, whereas none responded out of the 3 who had placebo. Possible side-reactions were limited with fenoverine: there were only 17 (18%) complaints, mainly dry mouth, of which 6 were very mild.(ABSTRACT TRUNCATED AT 250 WORDS)","PeriodicalId":19862,"journal":{"name":"Pharmatherapeutica","volume":"4 7","pages":"422-8"},"PeriodicalIF":0.0,"publicationDate":"1986-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14638199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A fixed-dose combination of furosemide and spironolactone in digitalized congestive heart failure patients. 速尿与螺内酯在数字化充血性心力衰竭患者中的固定剂量联合应用。

Pharmatherapeutica Pub Date : 1986-01-01

J Yasky, G A Ledesma, A Tutera, L F Collia

引用次数: 0

Pharmacokinetics and effects of isoxicam on renal function in patients with renal insufficiency. 异西康在肾功能不全患者中的药代动力学及对肾功能的影响。

Pharmatherapeutica Pub Date : 1986-01-01

P M Brooks, M McCredie, M Prowse, M Podgorski, M Forrest, I Munro, J Boutagy, L Pei-Ling

引用次数: 0